DYN · Dyne Therapeutics, Inc.

Dyne Therapeutics’ Q1 2026 financial results reflect continued investment in late-stage clinical development while scaling commercial readiness. Net loss improved modestly year-over-year to $120.9 million ($0.73 per share), driven primarily by a $5.6 million decline in R&D expenses — attributed to timing of manufacturing batches for z-rostudirsen and z-basivarsen — partially offset by a $8.5 million increase in G&A, explicitly tied to pre-launch activities for z-rostudirsen. The company ended the quarter with $972.2 million in cash and marketable securities, reaffirming its ability to fund operations into Q1 2028 without additional capital. Critically, the press release underscores de-risked clinical execution: the FDA pre-BLA meeting for z-rostudirsen was completed positively, confirming alignment on the BLA content and supporting the Q2 2026 submission timeline; long-term dystrophin data from the DELIVER trial show robust, durable protein restoration (9.48% unadjusted of normal), strengthening the biological rationale for Accelerated Approval. For z-basivarsen in DM1, enrollment in the ACHIEVE registrational expansion cohort has surpassed the 60-participant target, positioning Dyne for a Q1 2027 data readout to support an early Q3 2027 BLA filing. Management commentary emphasizes disciplined execution across both programs and a clear path toward two potential near-term launches — z-rostudirsen in Q1 2027 and z-basivarsen in Q1 2028 — contingent on regulatory review timelines and Priority Review designation. These developments collectively reinforce Dyne’s transition from clinical-stage biotech to a near-commercial organization with dual pivotal assets anchored by validated platform biology.